ERBB2 and cancer: The choice of the SK‐BR‐3 cell line, known for its sensitivity to monoclonal antibodies and other anti‐HER2 targeted therapies, aimed to deepen our understanding of cancer biology and the nuances of treatment responses, including potential synergies with immunotherapeutics and immune checkpoint inhibitors.